This study is testing **BP1002**, a new medicine, in people with advanced *lymphoid malignancies* (cancers affecting blood cells). Researchers want to see if BP1002 is safe, how it moves through the body (*pharmacokinetics*), and how well it works (*efficacy*). Up to 12 patients who have diseases like *lymphoma* or *leukemia* that have returned or not responded to treatment can join. Eligible participants must be 18 or older, not pregnant, and have tried several treatments before. They should also have good liver and kidney function. Some people cannot join, like those with other active cancers, certain infections, or who have taken experimental drugs recently.

• **Duration**: Participation requires multiple visits for assessments.
• **Compensation**: Participants may receive compensation for their time and travel.
• **Risks**: Potential side effects from the treatment, as with any clinical trial.

Participants must agree to use contraception during the study. If you're interested, you must provide written consent. This study aims to find better ways to treat these tough cancers.